Masaki Yamamoto

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Venues

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Shuntaro Hiro, Shuhei Teranishi, Tomoe Sawazumi, Satoshi Nagaoka, Chihiro Sugimoto, Hirokazu Nagayama, Wataru Segawa, Yukihito Kajita, Chihiro Maeda, Sousuke Kubo, Kenichi Seki, Ken Tashiro, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
Thymic atypical carcinoid tumors with elevated mitotic counts in a patient with multiple endocrine neoplasia: A case report. Thoracic cancer (2023)
Chihiro Sugimoto, Shuhei Teranishi, Tomoe Sawazumi, Satoshi Nagaoka, Hirokazu Nagayama, Wataru Segawa, Shuntaro Hiro, Yukihito Kajita, Chihiro Maeda, Sousuke Kubo, Kenichi Seki, Ken Tashiro, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
Primary tracheal small-cell carcinoma detected 11 months after surgery for pulmonary large-cell neuroendocrine carcinoma: A case report. Thoracic cancer (2023)
Nobuyuki Hirama, Masaki Yamamoto, Satoshi Nagaoka, Wataru Segawa, Chihiro Sugimoto, Hirokazu Nagayama, Shuntaro Hiro, Yukihito Kajita, Chihiro Maeda, Sousuke Kubo, Kenichi Seki, Yoshinori Nagahara, Shuhei Teranishi, Ken Tashiro, Yu Hara, Nobuaki Kobayash, Shigenobu Watanabe, Makoto Kudo, Takeshi Kaneko
Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non-small cell lung carcinoma. Thoracic cancer (2023)
Shuhei Teranishi, Chihiro Sugimoto, Satoshi Nagaoka, Hirokazu Nagayama, Wataru Segawa, Atsushi Miyasaka, Shuntaro Hiro, Yukihito Kajita, Chihiro Maeda, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. Thoracic cancer 13 (19) (2022)
Hiromi Matsumoto, Nobuaki Kobayash, Kohei Somekawa, Nobuhiko Fukuda, Ayami Kaneko, Chisato Kamimaki, Sousuke Kubo, Katsushi Tanaka, Yoichi Tagami, Shuhei Teranishi, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masaki Yamamoto, Makoto Kudo, Harumi Koizumi, Kenji Miura, Naoki Miyazawa, Takeshi Kaneko
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial. Thoracic cancer (2021)
Seigo Katakura, Nobuaki Kobayash, Hisashi Hashimoto, Chisato Kamimaki, Katsushi Tanaka, Sousuke Kubo, Kentaro Nakashima, Shuhei Teranishi, Saki Manabe, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer. Thoracic cancer 11 (10) (2020)
Nobuaki Kobayash, Hisashi Hashimoto, Chisato Kamimaki, Ryo Nagasawa, Katsushi Tanaka, Sousuke Kubo, Seigo Katakura, Hao Chen, Nobuyuki Hirama, Ryota Ushio, Ayako Aoki, Kentaro Nakashima, Shuhei Teranishi, Saki Manabe, Hiroki Watanabe, Nobuyuki Horita, Keisuke Watanabe, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial. Thoracic cancer 11 (8) (2020)

Masaki Yamamoto.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Masaki Yamamoto